Fulzerasib
Fulzerasib is an oral, covalent KRAS G12C inhibitor with potent activity against mutant tumor cell lines, demonstrating IC50 values in the low nanomolar range. It is a key research tool for investigating KRAS-driven oncogenesis and is utilized in both in vitro and in vivo studies for non-small cell lung cancer (NSCLC) and other solid tumors harboring the G12C mutation.
Product Specifications
CAS Number
2641747-54-6
Product Name Alternative
GFH 925, ,
Field of Research
Pharmacology & Drug Discovery, Signal Transduction
Purity
98.04% (May vary between batches)
Solubility
DMSO:100 mg/mL (162.06 mM)
Smiles
O=C (C=C) N1CCN2C=3C=4C=C (Cl) C (=NC4N (C (=O) C3N (C (=O) C2C1) C) C=5C (=NC=CC5C) C (C) C) C=6C (F) =CC=CC6O
Molecular Formula
C32H30ClFN6O4
Molecular Weight
617.07
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6455285-01 0.2 mL
Csnk2a1 (Casein Kinase II Subunit alpha, CK II alpha, Csnk2a1) (FITC)
Sign In for Pricing
View Details MBS6455285-02 5x 0.2 mL
Csnk2a1 (Casein Kinase II Subunit alpha, CK II alpha, Csnk2a1) (FITC)
Sign In for Pricing
View Details 
LV740147 1.0 µg DNA
PGK1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
Sign In for Pricing
View Details